Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Longitudinal cognitive assessment using the Cumulus NeuLogiq platform in amyotrophic lateral sclerosis and frontotemporal dementia.

Scientific reports·2026
Same author

Deep learning for the joint analysis of item-level longitudinal and survival data.

Journal of applied statistics·2026
Same author

Exploring physiotherapists' role in work-focused health care and fit note use: Barriers, facilitators, and recommendations.

Physiotherapy·2026
Same author

Multi-institutional MRI-based radiomic pilot study to measure the variations between scanner vendors and imaging sessions.

Frontiers in oncology·2026
Same author

The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial.

Nature medicine·2026
Same author

AI Ethics Guidelines: Time to Include Animals.

Science and engineering ethics·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Rianne N Esquivel1, Shriya Mathur1, Christine Parker2

  • 1GSK, Collegeville, PA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

像PrecivityAD和pTau181这样的血液生物标志物可以通过预先查粉样蛋白阳性来加速阿尔茨海默病的临床试验. 这减少了与传统确认性检测相关的患者负担和运营成本.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物标志物 生物标志物
  • 临床试验 临床试验

背景情况:

  • 早期阿尔茨海默氏症 (AD) 的临床试验由于粉样蛋白阳性率低,招生速度较慢.
  • 验证性检测 (心血管功能生物标志物,粉样蛋白PET) 增加了患者的负担和运营挑战.
  • 基于血液的生物标志物为预先查和丰富试验群体提供了潜在的解决方案.

研究的目的:

  • 评估血液基生物标志物 (PrecivityAD和Elecsys pTau181) 在早期AD临床试验中对粉样蛋白阳性进行预查的疗效.
  • 评估这些生物标志物对减少侵入性确认性测试需求的影响.

主要方法:

  • 纳入了PrecivityAD和Elecsys pTau181测试,用于PROGRESS-AD第二阶段试验的选过程.
  • 血液生物标志物结果与粉样蛋白PET和脑脊液 (Aβ42/40比) 的比较用于ROC分析.
  • 对证实性测试进行了积极百分比协议 (PPA),负百分比协议 (NPA) 和积极预测值 (PPV) 的分析.

主要成果:

  • pTau181显示了85.0%的PPA和59.5%的NPA.
  • 预测AD显示PPA为64.6%和NPA为42.9%.
  • PrecivityAD的PPV为96.4%,pTau181的PPV为90.0%,显著降低了屏幕故障率至9.9%.

结论:

  • 基于血液的生物标志物在早期AD试验中显著减少了对CSF或PET测试的需求.
  • 这些生物标志物可以降低参与者负担,改善试验可访问性,并提高临床试验设计.
  • 需要进一步的研究来解决局限性问题,例如对粉样蛋白阴性个体的不完整确认结果和潜在的偏见.